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Abstract
Introduction: The ProTWIN trial previously showed no beneficial effect of treat‐
ment with a cervical pessary vs usual care to prevent preterm birth in women with a 
multiple pregnancy. However, in women with a midtrimester short cervix (<38 mm), 
pessary did reduce the composite outcome of neonatal morbidity and mortality. This 
follow‐up study evaluates the long‐term outcomes of all children born to mothers 
who participated in the ProTWIN trial at 4 years of age.
Material and methods: Parents received the Ages and Stages Questionnaire, Strength 
and Difficulties Questionnaire and a health questionnaire. All questionnaires were 
reported separately and as a combined outcome (abnormal child outcome). A linear 
mixed effects model was used to adjust for correlated data in twins and correction 
for confounders was performed. In exploratory analysis, a composite outcome of 
death or survival with abnormal child outcome was used by combining extrapolated 
data on child outcome with survival data. All data were analyzed for the total group 
and the subgroup of women with midtrimester short cervix.
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1  | INTRODUC TION
Prematurity, defined as birth prior to 37 weeks of gestation, is the 
leading cause of perinatal morbidity, mortality and long‐term neu‐
rodevelopmental impairment, and is seen more often in women with 
a multiple pregnancy than in singletons (48.1% vs 6.0%).1
Several interventions are known for their use in preterm 
birth prevention such as progesterone, pessary and cerclage. 
Evaluations of these interventions in women with a multiple preg‐
nancy show no benefit of progesterone and a potentially harmful 
effect of cerclage.2 Studies evaluating the use of a cervical pes‐
sary are still ongoing. Although some pessary studies show prom‐
ising results,3,4 none of these studies reports long‐term childhood 
outcomes. The importance of long‐term outcomes related to 
agents given to pregnant women has been demonstrated by pre‐
vious studies, showing that a short‐term benefit can have unex‐
pected long‐term effects on children which may not be apparent 
at birth.5‐8
We previously reported the results of the ProTWIN trial, show‐
ing no beneficial effect of a cervical pessary in the short‐term in 
unselected women with an asymptomatic multiple pregnancy. In 
women with a midtrimester short cervix (cervical length <38 mm), a 
significant reduction in a composite of neonatal morbidity and mor‐
tality was seen in the pessary group (10% vs 24%, relative risk 0.42 
[95% confidence interval {CI} 0.19‐0.91]). A 3‐year follow‐up of the 
ProTWIN trial, analyzing children born to mothers with a midtrimes‐
ter short cervix, showed a significant reduction in the composite 
outcome of death or survival with a neurodevelopmental disability 
(10% vs 29%, odds ratio [OR] 0.26 [95% CI 0.09‐0.75]).9 However, 
this 3‐year follow‐up study did not report on all participants of the 
ProTWIN trial.
The aim of this follow‐up study was to compare developmen‐
tal, behavioral and physical outcomes of surviving children at age 
4 born to all mothers in the ProTWIN trial, comparing the cervi‐
cal pessary group with the control group. In addition, these out‐
comes are studied in the subgroup of women with short cervix 
(<38 mm). Finally, the composite outcome of death or abnormal 
developmental and/or behavioral and/or physical outcome at age 
4 is explored in the offspring of all randomized women of the 
ProTWIN trial, as well as in the subgroup of women with a short 
cervix.
2  | MATERIAL AND METHODS
We performed a follow‐up study of the ProTWIN trial, a multi‐
center randomized controlled clinical trial (NTR1858) conducted in 
40 hospitals in the Netherlands. Protocol and initial results of this 
study have been described in detail elsewhere.10,11 In short, the 
ProTWIN trial randomized women with an asymptomatic multiple 
pregnancy between pessary (n = 403) and usual care (n = 410). 
If assigned to the intervention group, a cervical pessary was in‐
serted between 16 and 20 weeks of gestation; women in the con‐
trol group received care as usual. Cervical length was measured at 
baseline using transvaginal sonography.11 Following the guideline 
of the Dutch Society for Obstetrics and Gynecology, no progester‐
one was administered.12
Results: Of the original 813 women of the ProTWIN trial, we approached 579, of 
whom 258 participated (45%) in follow‐up. We received questionnaires of 514 chil‐
dren (281 pessary vs 233 control), with 119 children in the subgroup of women with 
midtrimester short cervix. An abnormal child outcome was found in 23% in the pes‐
sary group vs 16% in the control group (odds ratio 1.58; 95% confidence interval 
0.94‐2.65). In exploratory analysis with extrapolated data on child outcome (n = 815), 
no difference in abnormal child outcome was seen between the pessary and control 
group. In the subgroup of women with a short cervix (n = 268), this composite out‐
come indicated a favorable outcome for children born to mothers with pessary.
Conclusions: In women with a multiple pregnancy, the use of a cervical pessary did 
not improve development, behavior or physical outcomes of the surviving children at 
age 4.
K E Y W O R D S
behavior, child, development, follow‐up, multiple pregnancy, pessary, preterm birth
Key message
In offspring of women with a multiple pregnancy rand‐
omized to cervical pessary or no intervention, cervical pes‐
sary did not improve child outcome in surviving children 
at age 4.
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2.1 | Follow‐up assessment
We aimed to evaluate all children born in the ProTWIN trial who 
were alive at discharge at a corrected age of 4 years, calculated 
from the expected date of delivery. Research nurses in partici‐
pating centers crosschecked medical records of all participating 
children of the original trial to track the possible occurrence of 
death of one or both children before contacting women. Mothers 
of whom at least one of the children was alive were contacted by 
telephone 3 months prior to the corrected age of 4 years. After 
consent, questionnaires were sent and filled out when the child 
was the corrected age of 4. Parents were asked to complete a 
paper version of the Ages and Stages Questionnaire 48 months 
(ASQ),13 the Strengths & Difficulties Questionnaire (SDQ)14 and 
a general health questionnaire. All mothers provided written in‐
formed consent.
2.2 | Ages and Stages Questionnaire
The ASQ is a developmental screening tool that covers five do‐
mains of child development, including communication, gross and 
fine motor development, problem‐solving and personal‐social skills. 
Each domain is assessed by six questions on developmental mile‐
stones.13 A validated Dutch translation of the ASQ 48 months was 
used. The construction of a binary ASQ developmental delay score 
was based on a comparison with the mean score and standard de‐
viation (SD) of the Dutch reference group. Scores of 1 SD below the 
mean of the ASQ normative data in two or more domains, or 2 SD 
below the normative mean in at least one domain were considered 
delayed.13,15
2.3 | Strengths & Difficulties Questionnaire
The SDQ is a questionnaire screening for behavioral problems in 
children. It consists of 25 items, grouped in five subscales: emotional 
problems, conduct problems, hyperactivity, peer problems and pro‐
social behavior. A total difficulties score can be calculated summing 
the first four subscales, leaving out pro‐social behavior.16 The vali‐
dated Dutch translation of the SDQ 4‐17 years was used. Total dif‐
ficulties score was coded according to the Dutch SDQ manual (0‐10 
normal, 11‐14 borderline and ≥15 abnormal) with mean values based 
upon data validated in the Netherlands.14 In the analysis, the total 
difficulties score was treated as a binary variable, with a cut‐off 
score of 15 to define abnormal.14,17
2.4 | Demographic and Health Questionnaire
A separate questionnaire was used to address demographic variables 
(for example, family composition, education of both parents, use of 
daycare, bilingualism and position within the family) and healthcare 
use of the children (for example visits to healthcare providers, medi‐
cation use in the past and present, hospital admission and surgery) 
until 4 years of age.
2.5 | Abnormal child outcome
The three assessment instruments were combined in a binary out‐
come (abnormal child outcome). A child was classified as abnormal 
when it showed a delayed ASQ developmental score, an abnormal 
SDQ total difficulties score or the presence of a physical problem 
(defined as ≥3 hospital admissions and/or ≥3 surgeries between dis‐
charge after birth and age 4).
We also studied a composite outcome integrating mortality data 
(stillbirth, death until 6 weeks after the expected term date and 
death before the age of 4 years) and abnormal child outcome at age 
4 as defined above.
2.6 | Statistical analyses
Abnormal cut‐off scores and mean scores of ASQ and SDQ question‐
naires were analyzed according to randomization in the ProTWIN 
trial for all surviving children that could be assessed at 4 years of 
age and in the subgroup of women with a cervical length <38 mm. 
Differences concerning maternal characteristics and neonatal short‐
term outcomes between pessary and control group of mothers and 
children that participated in the follow‐up were calculated with t 
test, Mann‐Whitney U test, Chi‐square test or Fisher's exact test 
when appropriate. Also differences in characteristics between fol‐
low‐up participants and participants lost to follow‐up were calcu‐
lated. A two‐sided P‐value <0.05 indicated statistical significance. A 
generalized linear mixed effects model (GLMM) was used to adjust 
for correlations between children of the same mother and confound‐
ers.18 Through a Directed Acyclic Graph (DAG), we visualized poten‐
tial confounders: due to the randomization process no confounders 
were found (Figure S1). However, prior to using DAG, we considered 
the influence of each potential confounder on the determinant‐out‐
come association individually, using 10% difference as a cut‐off for 
identification of confounders. In this analysis, the following variables 
were listed as potential confounders: parental education, smoking 
during pregnancy, ethnicity, bilingualism, whether the twins were 
the oldest children in the family, daycare participation and breast‐
feeding ≥6 months. A power calculation before the start of the fol‐
low‐up study showed that data of 225 children in each group would 
provide 80% power to detect a difference of 13% to 5% in delayed 
ASQ scores between the two groups with a two‐sided α of .05.
Results of the general health questionnaire were clustered.9 
We also performed an exploratory analysis evaluating the effect of 
pessary on a composite outcome of death or survival with abnor‐
mal child outcome in the offspring of all randomized women of the 
ProTWIN study and in the subgroup of women with cervical length 
<38 mm. Because baseline characteristics of children that partici‐
pated in the follow‐up, besides ethnicity, did not differ significantly 
from children that were lost to follow‐up (Table S1) we calculated 
a simple case extrapolation scenario, assuming children lost to 
follow‐up were showing the same percentage of disability as the 
group that was followed‐up. Furthermore, we also explored a best 
and worst case scenario in both groups, assuming all children lost to 
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follow‐up had either a normal child outcome (best case) or abnormal 
child outcome (worst case).
These extrapolated data were analyzed using a generalized linear 
mixed model calculating an OR. We adjusted the 95% CI by using 
the standard error of the assessed group of children at age 4 instead 
of the SE of the whole group that included extrapolated data. This 
was done to avoid misleading narrow confidence intervals due to the 
increase in patient numbers in the extrapolated data. Additionally, 
F I G U R E  1   Flowchart of participants in the ProTWIN trial (unselected and subgroup of women with short cervix), starting from 
randomization of women with a multiple pregnancy until the 4‐y follow‐up of the children [Color figure can be viewed at wileyonlinelibrary.
com]
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number needed to treat (NNT) or number needed to harm (NNH) 
and 95% CI were calculated. All statistical analyses were conducted 
in IBM SPSS version 21 (IBM Corp., Armonk, NY, USA).
2.7 | Ethical approval
Ethical approval for this follow‐up assessment was given by the 
Medical Ethics Committee of the Academic Medical Center in 
Amsterdam (NL46768.018.13).
3  | RESULTS
In the original ProTWIN trial, 813 women were randomly assigned to 
pessary (403 women, 815 children) or care as usual (410 women, 829 
children) (Figure 1). In total, 75 children (34 in the pessary group and 
41 in the control group) died due to stillbirth or death until 6 weeks 
after the expected term date. During the 4‐year follow‐up period, 
six children died (2 in the pessary group vs 4 in the control group). 
The risk of death was 36/815 in the pessary group and 45/829 in the 
control group (relative risk 0.87, 95% CI 0.58‐1.31).
Of the 813 women, 27 women lost both children, resulting in 
786 women with 1563 surviving children. Of these, 207 women with 
411 children were lost to follow‐up due to missing contact data. A 
total of 579 women (311 pessary vs 268 control) with 1152 children 
(621 pessary vs 531 control) were approached. Of the approached 
women, 321 refused participation (171 pessary vs 150 control) due 
to lack of time (n = 13, 4%), not interested (n = 21, 7%) or no reason 
provided (n = 287, 89%). Eventually, questionnaires were received 
from 258 mothers, reporting on 514 children (45% of women ap‐
proached, 281 pessary vs 233 control). For the subgroup of women 
with a cervical length of <38 mm, questionnaires from 61 mothers 
were received, reporting on 119 children (85 pessary vs 34 control) 
(Figure 1).
Mothers participating in follow‐up were more often of European 
origin compared with women that were lost to follow‐up (96% vs 
88%, P < 0.001) (Table S1). No other differences in maternal or 
neonatal characteristics between these two groups were found. 
When comparing maternal and neonatal characteristics of mothers 
and children participating in follow‐up, no differences were seen 
between the pessary and control groups. The mean age of children 
assessed for follow‐up was 3.98 (SD 0.19) years in the pessary group 
compared with 3.96 (SD .21) years in the control group (P = 0.198) 
(Table 1).
3.1 | Ages and Stages Questionnaires, 
Strength and Difficulties Questionnaires and General 
Health outcomes
No significant differences were found in delayed or mean ASQ scores, 
abnormal SDQ scores and physical problems between the pessary 
and control groups (Tables 2 and S2). No differences were seen in 
the individual SDQ subscales (results not shown) or the individual 
items of physical problems (ie, use of healthcare, medication and 
number of hospital admissions or surgeries) (Table S3). When abnor‐
mal scores of ASQ, SDQ and physical problems were combined, 64 
(23%) pessary children vs 37 (16%) control children were found to 
have an abnormal child outcome (OR 1.58 [95% CI 0.94‐2.65]). In 
the subgroup of women with a cervical length <38 mm, an abnormal 
child outcome was found for 13 (15%) in the pessary and 7 (21%) in 
the control children (OR 0.73 [95% CI 0.22‐2.48]; Table 2).
3.2 | A composite outcome of death or abnormal 
child outcome
We calculated the composite outcome of death or abnormal child 
outcome for all randomized women in the ProTWIN trial. In the pes‐
sary group, 36 of 815 children died. Extrapolation of the data for 
the 498 surviving children without follow‐up data, based on the per‐
centage abnormal child outcome found in the measured follow‐up 
children, resulted in a composite death or abnormal outcome in 214 
children (26%) of the 815 children. In the control group (n = 829), 45 
children died. Extrapolation of the abnormal child outcome for the 
551 surviving children without follow‐up data resulted in a compos‐
ite death or abnormal outcome in 170 children (21%) of the 829 chil‐
dren (OR 1.38 [95% CI 0.94‐2.03]) (Table 3), with a NNH of 18 [95% CI 
10.2‐60.0]. In the extrapolated data of the subgroup of children born 
to mothers with a cervical length <38 mm, the composite outcome 
occurred in 29 (19%) pessary children vs 40 (36%) control children 
(OR 0.40 [95% CI 0.17‐0.96]) (Table 3), with a NNT in this subgroup 
of 6 [95% CI 3.5‐14.8]. However, these results should be interpreted 
with caution, since an extrapolation technique is used to substitute 
for 67% of the children that were lost to follow‐up. When exploring 
best and worst case scenarios, a consistent beneficial effect of pes‐
sary was seen in the subgroup of women with short cervix (Table S4).
4  | DISCUSSION
In this follow‐up study, we assessed child outcomes at 4 years of 
age in children born to mothers randomized to treatment with a 
cervical pessary vs usual care. We found no beneficial effect of a 
pessary on development, behavior or physical outcomes (abnormal 
child outcome) in surviving children, irrespective of cervical length. 
When we combined death or abnormal child outcome in an explora‐
tory analysis, we found no improvement in this composite outcome 
in unselected women. However, in women with a short midtrimester 
cervical length, the use of a pessary did reduce the risk of a compos‐
ite outcome of death or abnormal child development in exploratory 
analysis.
In this follow‐up study, we were able to collect data on a broad 
range of child outcomes (development, behavior and physical) 4 years 
after child birth. Furthermore, the ProTWIN trial is the first study 
to report on the long‐term effects in children born to all mothers 
treated with a cervical pessary in their pregnancy to prevent preterm 
delivery. To date, two other randomized controlled trials have been 
     |  1297SIMONS et al.
TA B L E  1   ProTWIN maternal baseline characteristics, pregnancy outcomes and child neonatal and sociodemographic characteristics of 
the women participating in the 4‐y follow‐up study
Maternal characteristics at entry of the ProTWIN trial n/na
Pessary group  
(n = 140)
Control group 
(n = 118) P value
Median (IQR) maternal age at randomization 140/118 32 (29‐36) 33 (30‐37) 0.471
Nulliparity, n (%) 140/118 87 (62.1) 66 (55.9) 0.312
Smoking during pregnancy, n (%) 139/114 4 (2.9) 5 (4.4) 0.735
Previous preterm delivery, n (%)b 51/52 10 (19.6) 7 (13.5) 0.438
Parental education, n (%)c
High 134/115 102 (76.1) 89 (77.4) 0.908
Middle 20 (14.9) 15 (13.0)
Low 12 (9.0) 11 (9.6)
Ethnic origin European, n (%) 140/118 132 (94.3) 106 (89.8) 0.234
Monochorionic pregnancy, n (%) 139/118 33 (23.7) 30 (25.4) 0.755
Triplet pregnancy, n (%) 140/118 5 (3.6) 2 (1.7) 0.459
Cervical length (mm), median (IQR)
Unselected group 140/118 43 (37‐48.75) 43 (39‐49) 0.268
Subgroup cervical length <38 mm 43/18 35 (33‐37) 34 (32‐35.25) 0.100
Maternal pregnancy outcomes ProTWIN trial
Pregnancy duration in weeks median (IQR) 140/118 36.6 (34.4‐37.6) 36.3 (34.2‐37.4) 0.417
<28 wk, n (%) 2 (1.4) 2 (1.7) >0.999
<32 wk, n (%) 14 (10.0) 13 (11.0) 0.790
<37 wk, n (%) 71 (50.7) 62 (52.5) 0.770
PPROM, n (%) 125/99 16 (12.8) 12 (12.1) 0.879
Tocolytic drug, n (%) 140/118 23 (16.4) 21 (17.8) 0.771
Corticosteroids, n (%) 131/113 33 (25.2) 35 (31.0) 0.315
Neonatal characteristics of the ProTWIN trial n/n
Pessary group  
(n = 281)
Control group 
(n = 233) P value
Male gender, n (%) 281/233 138 (49.1) 122 (52.4) 0.463
Composite primary outcome of the ProTWIN trial, n (%)d 279/233 15 (5.4) 15 (6.4) 0.611
Congenital anomalies, n (%) 277/233 9 (3.2) 9 (3.9) 0.811
Birthweight, n (%)
<2500 g 280/233 147 (52.5) 134 (57.5) 0.256
<1500 g 32 (11.4) 22 (9.4) 0.465
Social background of the children at 4 y of age
Age at follow‐up, mean (SD) 281/233 3.98 (0.19) 3.96 (0.21) 0.198
Living in two parent family, n (%)e 275/233 269 (97.8) 230 (98.7) 0.517
Twins are eldest of the siblings, n (%) 277/233 169 (61.0) 128 (54.9) 0.166
Dutch primary language spoken at home, n (%) 275/231 269 (97.8) 229 (99.1) 0.300
Bilingual, n (%) 277/233 40 (14.4) 34 (14.6) 0.961
Daycare, n (%) 277/233 256 (92.4) 217 (93.1) 0.757
Breastfed in the first 6 mo, n (%)f 276/230 61 (22.1) 42 (18.3) 0.258
aNumber of analyzed mothers or children, without missing data. Pessary group/control group. 
bPrevious preterm delivery, excluding all nulliparous women. 
cParental education: “low level” = total years post elementary schooling <6, if at least one of the parents has a low level of education (but not if one 
parent is highly educated); “middle level” = total years post elementary schooling 6‐8, if both parents have a middle level of education; “high level” = 
total years post elementary schooling >8, if one of the parents is highly educated.26 Parental education at the time of follow‐up. 
dComposite outcome of the ProTWIN trial: stillbirth, PVL grade ≥2, RDS grade ≤2, BPD, IVH grade 2B or worse, NEC, proven sepsis, neonatal death 
until 6 weeks after expected term date.11 
eLiving in two parent family: Children living with one or two biological parents, new marriage and de facto relationship. 
fBreastfed in the first 6 mo: breastfeeding for at least 6 mo, with or without infant formula. 
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published evaluating the use of a pessary in women with a twin preg‐
nancy3,19 and four trials in singletons as prevention of preterm birth 
strategy.20‐23 These trials have not (yet) reported long‐term follow‐up.
A limitation of this study is the high rate of loss to follow‐up, 
with a difference in follow‐up rate between the pessary and con‐
trol group in all eligible women (36% vs 30% in pessary and control, 
respectively) but not between randomization groups in the women 
approached (45% vs 44%, pessary and control, respectively). In the 
4 years after randomization, many families moved at least once, and 
their addresses and phone numbers could not be retrieved despite 
several efforts. Furthermore, due to logistic reasons, one center that 
initially recruited 30 women did not collaborate in the follow‐up 
study. We expect that these data will be missing at random and will 
not contribute to substantial bias. However, women who refused 
participation (55% of those approached) can have caused an attrition 
bias. With respect to the baseline characteristics, we found that a 
higher proportion of highly educated mothers participated in the fol‐
low‐up study (69%) compared with the original trial (61%); however, 
this difference was not significant. This may have influenced the re‐
sults by giving more favorable ASQ and SDQ scores in this follow‐up 
sample, as high education of parents is known to be associated with 
better cognitive and behavioral outcomes.24 Furthermore, mothers 
participating in follow‐up were more often of European origin com‐
pared with women who were lost to follow‐up (96% vs 88%).
Another drawback of the loss to follow‐up in this study was the 
inability to define the denominator of the rate of developmental prob‐
lems (whereas the denominator of mortality was known, since we had 
information about the survival status at 4 years of age of all offspring). 
Because of the magnitude of this missing information, multiple impu‐
tation techniques were considered inadequate. Instead, we could only 
do exploratory analyses evaluating several scenarios with the data ex‐
trapolated to all women randomized in the original ProTWIN trial and 
to a subgroup of women with a short midtrimester cervical length.
Another limitation is the sole use of questionnaires as screen‐
ing tool for developmental delay and behavioral problems instead of 
additional physical developmental tests or behavioral observations. 
Questionnaires provide less detailed and accurate information but 
do give information from parents who know their children well and 
are in addition less time‐consuming for both parents and children. 
Furthermore, the ASQ and SDQ are widely used in follow‐up studies 
and validated in several countries, including the Netherlands, with 
norms based on a Dutch population.
Unfortunately, we cannot draw an affirmative conclusion for the 
use of a pessary in women with a multiple pregnancy concerning the 
TA B L E  2   Outcomes of Ages and Stages Questionnaire (ASQ), Strengths and Difficulties Questionnaire (SDQ) and physical outcomes 
in children at 4‐y follow‐up between pessary and control group. Results shown for unselected group of mothers and in the subgroup of 






OR unadjusted for  
confounders (95% CI)
OR adjusted for  
confounders (95% CI)c
ASQ, delayed, n (%)b 277/229 41 (14.8) 23 (10) 1.54 (0.83‐2.85) 1.44 (0.77‐2.70)1
SDQ, abnormal, n (%)b 279/229 19 (6.8) 10 (4.4) 1.37 (0.66‐2.82) 1.31 (0.64‐2.71)2
Physical problemd 277/229 12 (4.3) 6 (2.6) 1.28 (0.57‐2.91) —3
Abnormal child outcomee 281/233 64 (22.9) 37 (15.9) 1.58 (0.94‐2.65) —4





OR unadjusted for  
confounders (95% CI)
OR adjusted for  
confounders (95% CI)c
ASQ, delayed, n (%)b 85/34 9 (10.6) 3 (8.8) 1.26 (0.27‐5.96) 1.62 (0.34‐7.64)5
SDQ, abnormal, n (%)b 85/34 4 (4.7) 0 2.08 (0.22‐19.34) 1.92 (0.20‐18.27)6
Physical problemd 85/34 2 (2.4) 4 (11.8) 0.33 (0.07‐1.47) 0.42 (0.09‐2.03)7
Abnormal child outcomee 85/34 13 (15.3) 7 (20.6) 0.73 (0.22‐2.48) 0.95 (0.24‐3.69)8
aNumber of analyzed children, without missing data. Pessary group/control group. 
bNormal or delayed ASQ scores were based on the mean score and SD of the Dutch reference group. Scores of 1 SD below the mean in two or more 
domains, or 2 SD below the mean in at least one domain were considered delayed.15 SDQ scores were coded (normal, borderline and abnormal) 
according to the SDQ manual with mean values based upon data validated in a Dutch population.14,16 Total difficulties score was calculated summing 
up the first four subscales, excluding pro‐social behavior. 
cOdds ratio adjusted for the following confounders: 
dDefined as ≥3 hospital admissions or ≥3 surgeries in the past 4 years. 
eDelayed ASQ score or abnormal SDQ total difficulties score or a physical problem (as defined above).
1. Breastfeeding more than 6 mo (with or without infant formula); 
2. Ethnicity
3. No significant confounders with beta difference >10%; 
4. No significant confounders with beta difference >10%
5. Breastfeeding more than 6 mo (with or without infant formula), use of daycare and ethnicity; 
6. Parental education and use of daycare; 
7. Daycare and breastfeeding more than 6 mo (with or without infant formula); 
8. Daycare and breastfeeding more than 6 mo (with or without infant formula).  
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long‐term outcomes of their children. We experienced a high loss to 
follow‐up and therefore decided to use an exploratory extrapolating 
technique to impute missing outcomes.
The original ProTWIN trial showed a reduced short‐term neo‐
natal mortality and morbidity with the use of a cervical pessary in 
women with a short cervix (<38 mm). The 3‐year follow‐up study of 
the ProTWIN trial, evaluating Bayley developmental scores in chil‐
dren born to mothers with a short cervical length only, showed no 
signs of harm caused by the pessary: surviving children had com‐
parable neurodevelopmental outcomes. Translating these results 
into clinical practice combining the risk of death and an abnormal 
developmental outcome, six to eight women with a short cervix 
need to be treated with a cervical pessary to prevent one child 
from death or survival with neurodevelopmental disability.9 In our 
4‐year follow‐up, the NNT in the subgroup with a short cervix is 
6 and is therefore consistent with the previously reported NNT.
Unfortunately, long‐term follow‐up is not very common in obstet‐
ric studies25 and data of other trials evaluating the long‐term effect of 
pessary is lacking. Worldwide, more trials on the use of a pessary are in 
progress (for example, trials registered with numbers NCT02901626, 
NCT02901626, NCT02901626, NCT02518594, NCT02328989, 
NTR4414, IRAS ID 156783, NCT02235181, NCT00735137) evaluat‐
ing not only the use of a pessary but also the use of progestogens and 
cerclage. Our data can hopefully contribute to future meta‐analysis 
on long‐term follow‐up of pessary interventions.
5  | CONCLUSION
In women with a multiple pregnancy, the use of a cervical pessary 
did not improve development, behavior or physical outcomes of the 
surviving children at age 4. Exploratory analysis with simple imputa‐
tion technique showed promising results for children born to women 
with a short cervix; however, no conclusions can be drawn from this 
analysis. A follow‐up study on a randomized trial evaluating the use 
of pessary in women with a short midtrimester cervix is needed to 
confirm our results.
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